Registered number
10840710
Medicalchain.com Limited
Filleted Accounts
31 December 2023
Medicalchain.com Limited
Registered number: 10840710
Balance Sheet
as at 31 December 2023
Notes 2023 2022
£ £
Fixed assets
Intangible assets 3 - 1,775,036
Tangible assets 4 16,031 23,426
Investments 5 252,627 1,332,627
268,658 3,131,089
Current assets
Debtors 6 410,113 113,403
Cash at bank and in hand 4,252 845
414,365 114,248
Creditors: amounts falling due within one year 7 (3,882,449) (3,513,457)
Net current liabilities (3,468,084) (3,399,209)
Net liabilities (3,199,426) (268,120)
Capital and reserves
Called up share capital 17,004 17,004
Profit and loss account (3,216,430) (285,124)
Shareholders' funds (3,199,426) (268,120)
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Mr Abdullah Albeyatti
Director
Approved by the board on 23 February 2025
Medicalchain.com Limited
Notes to the Accounts
for the year ended 31 December 2023
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover, if any includes revenue earned from the sale of goods and from the rendering of services. Turnover, if any from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover, if any from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Intangible fixed assets
Intangible assets include purchased computer software, capitalised website costs and software licences. The identifiable and directly associated external and internal costs of acquiring and developing software are capitalised and recognised as an intangible asset where the software is controlled by the Company, and where it is probable that future economic benefits will flow from its use over more than one year. Costs associated with maintaining software are recognised as an expense as incurred.

During the year, the company lost its contract with the NHS, which was a significant source of revenue. Despite this development, the directors have carefully assessed the carrying value of the website and software under development.

The directors are of the opinion that these intangible assets are now obsolete due to the loss of the contract and the lack of foreseeable use or revenue generation potential. As a result, the full carrying amounts of the website and software have been written off during the year.

This write-off reflects the directors’ commitment to ensuring that the financial statements present a true and fair view of the company’s financial position in line with applicable accounting standards.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Office equipment 33.33% at reducing balance method.
Leasehold improvements 33.33% at reducing balance method.
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

The company invested £1,080,000 into a related party company with the purpose of having this amount directly invested into Blippar.com. Subsequently, Blippar.com entered liquidation, resulting in the complete loss of the invested amount.

As the value of the investment became nil, the related party company cancelled the shares issued against this investment, reflecting the loss in full.

This loss has been fully recognised in the financial statements for the year, ensuring the company’s financial position is presented fairly in accordance with applicable accounting standards.
Going Concern
The directors have assessed the company’s ability to continue as a going concern and have identified significant uncertainties that cast substantial doubt on its ability to do so.

During the year, the company lost its NHS contract, which was its primary source of revenue, with no prospects of securing alternative revenue streams in the foreseeable future. In addition, the company’s investment of £1,080,000 became worthless following the liquidation of Blippar.com, and the website and software under development have been written off due to obsolescence.

Furthermore, the company is facing mounting debts payable to its parent company, which it appears unable to repay under current circumstances.

Given these factors, the directors acknowledge that the company is insolvent, and there is material uncertainty regarding its ability to continue as a going concern. As a result, the financial statements have been prepared on a basis other than going concern, reflecting the company’s current financial position.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Leased assets
A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.
Impairment of non-financial asset
At the end of each reporting period, the Company assesses whether there is any indication that an asset may be impaired. The assessment will include the consideration of external and internal sources of information. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use to the asset's carrying value. Value in use is calculated by discounting the estimated future cash flows of the asset at a pre-tax discount rate reflected the specific risks in the asset. Any excess of the asset's carrying value over its recoverable amount is expensed to the Income statement.
Impairment testing is performed annually for intangible assets and indefinite lives. Assets that have an allocated impairment loss are reviewed for reversal indicators at the end of each reporting period. After recognition of an impairment loss, the amortisation charge for the asset is adjusted in future periods to allocate the asset's revised carrying amount on a systematic basis over its remaining useful life.

Impairment losses are recognised as an expense immediately.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2023 2022
Number Number
Average number of persons employed by the company - 7
3 Intangible fixed assets £
WIP & Website:
Cost
At 1 January 2023 1,775,036
At 31 December 2023 1,775,036
Amortisation
Provided during the year 1,775,036
At 31 December 2023 1,775,036
Net book value
At 31 December 2023 -
At 31 December 2022 1,775,036
During the year, the company lost its contract with the NHS, which was a significant source of revenue. Despite this development, the directors have carefully assessed the carrying value of the website and software under development.

The directors are of the opinion that these intangible assets are now obsolete due to the loss of the contract and the lack of foreseeable use or revenue generation potential.

As a result, the full carrying amounts of the website and software have been written off during the year.

This write-off reflects the directors’ commitment to ensuring that the financial statements present a true and fair view of the company’s financial position in line with applicable accounting standards.
4 Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2023 43,029
Additions 619
At 31 December 2023 43,648
Depreciation
At 1 January 2023 19,603
Charge for the year 8,014
At 31 December 2023 27,617
Net book value
At 31 December 2023 16,031
At 31 December 2022 23,426
5 Investments
Other
investments
£
Cost
At 1 January 2023 1,332,627
Disposals (1,080,000)
At 31 December 2023 252,627
Historical cost
At 1 January 2023 1,332,627
At 31 December 2023 252,627
6 Debtors 2023 2022
£ £
Trade debtors - 34,903
Other debtors 410,113 78,500
410,113 113,403
7 Creditors: amounts falling due within one year 2023 2022
£ £
Trade creditors 9,780 16,456
Due to related parties 3,779,511 3,409,442
Taxation and social security costs 93,158 87,559
3,882,449 3,513,457
8 Annual Leave provision 2023 2022
£ £
At 1 January 2023 28,161 -
Utilised during the year (28,161) -
Additional provisions - -
At 31 December 2023 - -
8 Related party transactions
FRS 102 (paragraph 33.1A) exempts the reporting of transactions between group companies provided that any subsidiary which is party to the transaction is wholly owned by such a member. The Company has taken advantage of this exemption.

As at 31 December 2023, the company was owed £79,000 from another related party company (£78,500:2022). The amount is interest free and repayable om demand.

As at 31 December 2023, the company owed £3,734,738 (£2,357,568: 2022) to the related parties which is repayable on demand and have attracted no interest during the period.

As at 31 December 2023, the company owed £43,202 to the directors (£0:2023). The amount is interest free and repayable om demand.

As at 31 December 2023, the company was owed £331,113 from another related party company (£358,849:2023). The amount is interest free and repayable om demand.

The company invested £1,080,000 into a related party company with the purpose of having this amount directly invested into Blippar.com. Subsequently, Blippar.com entered liquidation, resulting in the complete loss of the invested amount.

As the value of the investment became nil, the related party company cancelled the shares issued against this investment, reflecting the loss in full.

This loss has been fully recognised in the financial statements for the year, ensuring the company’s financial position is presented fairly in accordance with applicable accounting standards.
9 Controlling party
Medicalchain SA is the ultimate controlling party of the company by virtue of its shareholdings in the company.
10 Other information
Medicalchain.com Limited is a private company limited by shares and incorporated in England. Its registered office is:
49 Grosvenor Street
London
W1K 3HP
Medicalchain.com Limited 10840710 false 2023-01-01 2023-12-31 2023-12-31 VT Final Accounts July 2024 Mr Abdullah Albeyatti No description of principal activity 10840710 2022-01-01 2022-12-31 10840710 core:WithinOneYear 2022-12-31 10840710 core:ShareCapital 2022-12-31 10840710 core:RetainedEarningsAccumulatedLosses 2022-12-31 10840710 2023-01-01 2023-12-31 10840710 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 10840710 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 10840710 bus:Director40 2023-01-01 2023-12-31 10840710 1 2023-01-01 2023-12-31 10840710 2 2023-01-01 2023-12-31 10840710 core:Goodwill 2023-01-01 2023-12-31 10840710 core:PlantMachinery 2023-01-01 2023-12-31 10840710 countries:England 2023-01-01 2023-12-31 10840710 bus:FRS102 2023-01-01 2023-12-31 10840710 bus:FilletedAccounts 2023-01-01 2023-12-31 10840710 2023-12-31 10840710 core:WithinOneYear 2023-12-31 10840710 core:ShareCapital 2023-12-31 10840710 core:RetainedEarningsAccumulatedLosses 2023-12-31 10840710 core:Goodwill 2023-12-31 10840710 core:PlantMachinery 2023-12-31 10840710 core:DisposalsRepaymentsInvestments 2023-12-31 10840710 2022-12-31 10840710 core:Goodwill 2022-12-31 10840710 core:PlantMachinery 2022-12-31 iso4217:GBP xbrli:pure